Intellia Therapeutics misses by $0.16, misses on revs
- Reports Q4 (Dec) loss of $0.61 per share, $0.16 worse than the Capital IQ Consensus of ($0.45); revenues rose 19.6% year/year to $6.7 mln vs the $8.84 mln Capital IQ Consensus.
- As of December 31, 2017, the Company had an accumulated deficit of $121.1 million. The Company expects losses to increase as it continues to incur significant research and development expenses related to the advancement of Intellia's therapeutic programs and ongoing operations. Based on Intellia's research and development plans and expectations related to the progress with the Company's programs, the Company expects that the cash and cash equivalents as of December 31, 2017, as well as technology access and research funding from Novartis and Regeneron, will enable Intellia to fund operating expenses and capital expenditures through mid-2020, excluding any potential milestone payments or extension fees that could be earned and distributed under the collaboration agreements with Novartis and Regeneron or any strategic use of capital not currently in the base case planning assumptions.
No comments:
Post a Comment